Basiliximab Treating Interstitial Pneumonia of CADM
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This is a 52-week, randomized, open and routine treatment controlled study. This study will
assess the safety and efficacy of basiliximab as an add-on treatment for interstitial
pneumonia in clinical amyopathic dermatomyositis (CADM) patients. 100 CADM patients are
planned to be enrolled in a single center.